News Releases

Date Title and Summary Additional Formats
March 2, 2021 Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
REHOVOT, Israel and WILMINGTON, Del., March 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that
February 19, 2021 Ayala Pharmaceuticals Announces $25 Million Strategic Financing
Funding Extends Cash Runway through Multiple Expected Value Drivers Into 2023 Funds Expected to Support the Recently Announced Accelerated Development of AL102 for the Treatment of Desmoid Tumors into Pivotal Phase 2/3 Study REHOVOT, Israel and WILMINGTON, Del., Feb.
January 28, 2021 Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer
REHOVOT, Israel and WILMINGTON, Del., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the
January 13, 2021 Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor Conference
REHOVOT, Israel and WILMINGTON, Del., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
January 5, 2021 Ayala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect Conference
REHOVOT, Israel and WILMINGTON, Del., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
January 4, 2021 Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
- FDA Agreement from End-of-Phase 1 Meeting to Advance to Potential Registrational Study - - Pivotal Trial Expected to Initiate in 1H21 - REHOVOT, Israel & WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on